<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In 1974 we suggested a schedule of the pathogenesis of <z:mp ids='MP_0005481'>CML</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain><z:mp ids='MP_0005481'>CML</z:mp> was described as a variant of the cutaneous lymphadenoid infiltrate (Fig. 2) </plain></SENT>
<SENT sid="2" pm="."><plain>Four years later, the schedule still appears to be valid, even to explain the three types of <z:e sem="disease" ids="C0221269" disease_type="Disease or Syndrome" abbrv="">pseudolymphoma</z:e> (Table 3) </plain></SENT>
<SENT sid="3" pm="."><plain>Recent findings concering </plain></SENT>
<SENT sid="4" pm="."><plain>Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and <z:e sem="disease" ids="C0026948" disease_type="Neoplastic Process" abbrv="">Mycosis fungoides</z:e> fit in well with the proposed schedule </plain></SENT>
<SENT sid="5" pm="."><plain>In studying <z:mp ids='MP_0005481'>CML</z:mp> recognition of the malignant lymphomatous cell is most important </plain></SENT>
<SENT sid="6" pm="."><plain>Progress in immunology should make it possible to destroy these malignant cells by immunological measures since the cells belong to one clone </plain></SENT>
</text></document>